Iantrek Expands Clinical Evidence for AlloFlo Uveo with Two New Peer-Reviewed Publications
Iantrek announced the publication of two new peer-reviewed studies the company says strengthens the clinical evidence base for AlloFlo Uveo, bringing the total number of peer-reviewed publications to seven.
According to Iantrek, the first paper, published in Clinical Ophthalmology, delivers Level I clinical evidence through the largest systematic review and meta-analysis of ab-interno uveoscleral outflow enhancement to date. The analysis spans more than a century of surgical experience, incorporating over 4,000 eyes across 40 cyclodialysis studies.
“The analysis confirms cyclodialysis as an effective procedure for enhancing uveoscleral outflow, with modern ab-interno approaches showing improved intraocular pressure (IOP)-lowering efficacy, safety, and durability," said lead author Robert Stamper, MD, Professor of Ophthalmology at UCSF.
A second peer-reviewed study reports 1-year prospective outcomes in 51 eyes with uncontrolled primary open-angle glaucoma treated with bio-reinforced cyclodialysis using AlloFlo Uveo.
Key findings include:
IOP reduction: from 25.7 mmHg at baseline to 15.4 mmHg at 12 months (40% relative decrease)
Medication reduction: 42% fewer IOP-lowering medications required at 1 year
According to Iantrek, the addition of these studies strengthens the clinical foundation of AlloFlo Uveo, building on evidence generated from the ongoing CREST Study.
Iantrek is planning a formal commercial launch of the AlloFlo Uveoat at the upcoming American Academy of Ophthalmology (AAO) annual meeting. According to Iantrek, nearly 3,000 procedures have already been performed in the United States.
“The growing body of peer-reviewed evidence represents an important step in glaucoma care. Patients should have access to a full range of surgical options, including approaches that engage the uveoscleral pathway," said Arsham Sheybani, MD, Washington University in St. Louis. "Supported by real-world evidence data from the CREST Study, AlloFlo Uveo appears to be a valuable addition to our surgical armamentarium."